Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating restated by equities researchers at HC Wainwright in a research note issued on Monday,Benzinga reports.

A number of other research analysts also recently issued reports on SRPT. Wedbush boosted their target price on shares of Sarepta Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Guggenheim reduced their price objective on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Barclays started coverage on Sarepta Therapeutics in a report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 target price on the stock. Finally, Mizuho raised Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $19.00 to $26.00 in a report on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have given a Sell rating to the stock. According to data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Hold” and an average price target of $32.85.

Sarepta Therapeutics Trading Down 2.8%

Sarepta Therapeutics stock opened at $15.87 on Monday. The stock has a 50-day moving average price of $20.21 and a 200 day moving average price of $20.15. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -1.88, a price-to-earnings-growth ratio of 0.26 and a beta of 0.42. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $107.77. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). The business had revenue of $442.93 million for the quarter, compared to analysts’ expectations of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The business’s quarterly revenue was down 32.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.90 earnings per share. Sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Buying and Selling

In other news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares in the company, valued at $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its holdings in Sarepta Therapeutics by 214.2% in the 1st quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock worth $344,000 after acquiring an additional 3,671 shares in the last quarter. Great Lakes Advisors LLC purchased a new position in Sarepta Therapeutics during the first quarter valued at $224,000. State of New Jersey Common Pension Fund D grew its position in shares of Sarepta Therapeutics by 59.9% in the second quarter. State of New Jersey Common Pension Fund D now owns 48,555 shares of the biotechnology company’s stock valued at $830,000 after purchasing an additional 18,190 shares during the period. New York Life Investment Management LLC increased its stake in shares of Sarepta Therapeutics by 10.0% during the second quarter. New York Life Investment Management LLC now owns 10,623 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 966 shares in the last quarter. Finally, Retirement Systems of Alabama raised its position in shares of Sarepta Therapeutics by 3.3% during the 2nd quarter. Retirement Systems of Alabama now owns 120,118 shares of the biotechnology company’s stock worth $2,054,000 after purchasing an additional 3,859 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.